Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men

Anne Roivainen, Esa Kähkönen, Pauliina Luoto, Sandra Borkowski, Birte Hofmann, Ivan Jambor, Kaisa Lehtiö, Tuija Rantala, Antje Rottmann, Henri Sipilä, Rick Sparks, Sami Suilamo, Tuula Tolvanen, Ray Valencia and Heikki Minn
Journal of Nuclear Medicine June 2013, 54 (6) 867-872; DOI: https://doi.org/10.2967/jnumed.112.114082
Anne Roivainen
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esa Kähkönen
2Department of Urology, Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pauliina Luoto
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Borkowski
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Birte Hofmann
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan Jambor
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaisa Lehtiö
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
4Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tuija Rantala
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antje Rottmann
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henri Sipilä
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rick Sparks
5CDE Dosimetry Services, Inc., Knoxville, Tennessee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sami Suilamo
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
4Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tuula Tolvanen
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ray Valencia
3Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heikki Minn
1Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
4Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 54 (6)
Journal of Nuclear Medicine
Vol. 54, Issue 6
June 1, 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
Anne Roivainen, Esa Kähkönen, Pauliina Luoto, Sandra Borkowski, Birte Hofmann, Ivan Jambor, Kaisa Lehtiö, Tuija Rantala, Antje Rottmann, Henri Sipilä, Rick Sparks, Sami Suilamo, Tuula Tolvanen, Ray Valencia, Heikki Minn
Journal of Nuclear Medicine Jun 2013, 54 (6) 867-872; DOI: 10.2967/jnumed.112.114082

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Plasma Pharmacokinetics, Whole-Body Distribution, Metabolism, and Radiation Dosimetry of 68Ga Bombesin Antagonist BAY 86-7548 in Healthy Men
Anne Roivainen, Esa Kähkönen, Pauliina Luoto, Sandra Borkowski, Birte Hofmann, Ivan Jambor, Kaisa Lehtiö, Tuija Rantala, Antje Rottmann, Henri Sipilä, Rick Sparks, Sami Suilamo, Tuula Tolvanen, Ray Valencia, Heikki Minn
Journal of Nuclear Medicine Jun 2013, 54 (6) 867-872; DOI: 10.2967/jnumed.112.114082
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry
  • Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease
  • First-in-Human Serum Stability Studies of [177Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy
  • Preclinical Comparison of the 64Cu- and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT
  • Substitution of L-Tryptophan by {alpha}-Methyl-L-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability
  • GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naive Patients
  • MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
  • Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
  • Radiosynthesis and Preclinical Evaluation of [68Ga]Ga-NOTA-Folate for PET Imaging of Folate Receptor {beta} Positive Macrophages
  • Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
  • Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
  • Will GRPR Compete with PSMA as a Target in Prostate Cancer?
  • Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist
  • Bombesin-Targeted PET of Prostate Cancer
  • Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer
  • 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients
  • Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB
  • Preclinical Comparison of Al18F- and 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer
  • N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of 68Ga- and 64Cu-Labeled Peptides for PET Imaging
  • A High-Affinity, High-Stability Photoacoustic Agent for Imaging Gastrin-Releasing Peptide Receptor in Prostate Cancer
  • In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

Keywords

  • dosimetry
  • 68Ga
  • PET
  • pharmacokinetics
  • radiometabolism
  • whole-body distribution
SNMMI

© 2025 SNMMI

Powered by HighWire